FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207040364> ?p ?o ?g. }

• W4207040364 endingPage "58" @default.
• W4207040364 startingPage "52" @default.
• W4207040364 abstract "Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),§ and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6). Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated. The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design¶ among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance. Patients with MIS-C (case-patients) and two groups of hospitalized controls matched to case-patients were evaluated: test-negative controls had at least one COVID-19-like symptom and negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen-based assay results, and syndrome-negative controls were hospitalized patients without COVID-19-like illness. Among 102 MIS-C case-patients and 181 hospitalized controls, estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%-97%). All 38 MIS-C patients requiring life support were unvaccinated. Receipt of 2 doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18 years, highlighting the importance of vaccination among all eligible children." @default.
• W4207040364 created "2022-01-26" @default.
• W4207040364 creator A5005225798 @default.
• W4207040364 creator A5006764971 @default.
• W4207040364 creator A5009301455 @default.
• W4207040364 creator A5012827962 @default.
• W4207040364 creator A5016004110 @default.
• W4207040364 creator A5019369010 @default.
• W4207040364 creator A5019807753 @default.
• W4207040364 creator A5022979690 @default.
• W4207040364 creator A5026626377 @default.
• W4207040364 creator A5026668616 @default.
• W4207040364 creator A5030293270 @default.
• W4207040364 creator A5033603299 @default.
• W4207040364 creator A5035425491 @default.
• W4207040364 creator A5040815474 @default.
• W4207040364 creator A5043871716 @default.
• W4207040364 creator A5044227648 @default.
• W4207040364 creator A5052756461 @default.
• W4207040364 creator A5057439250 @default.
• W4207040364 creator A5064650836 @default.
• W4207040364 creator A5070194844 @default.
• W4207040364 creator A5071618232 @default.
• W4207040364 creator A5072931455 @default.
• W4207040364 creator A5073278312 @default.
• W4207040364 creator A5078564323 @default.
• W4207040364 creator A5079101221 @default.
• W4207040364 creator A5081936870 @default.
• W4207040364 creator A5083639360 @default.
• W4207040364 creator A5087750390 @default.
• W4207040364 creator A5088402750 @default.
• W4207040364 creator A5088977709 @default.
• W4207040364 creator A5089135490 @default.
• W4207040364 creator A5089957220 @default.
• W4207040364 creator A5091740212 @default.
• W4207040364 creator A9999999999 @default.
• W4207040364 date "2022-01-14" @default.
• W4207040364 modified "2023-10-16" @default.
• W4207040364 title "Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021" @default.
• W4207040364 cites W3037731101 @default.
• W4207040364 cites W3038003713 @default.
• W4207040364 cites W3144463172 @default.
• W4207040364 cites W3164720238 @default.
• W4207040364 cites W3187850115 @default.
• W4207040364 cites W3206899651 @default.
• W4207040364 cites W4200329071 @default.
• W4207040364 doi "https://doi.org/10.15585/mmwr.mm7102e1" @default.
• W4207040364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35025852" @default.
• W4207040364 hasPublicationYear "2022" @default.
• W4207040364 type Work @default.
• W4207040364 citedByCount "189" @default.
• W4207040364 countsByYear W42070403642022 @default.
• W4207040364 countsByYear W42070403642023 @default.
• W4207040364 crossrefType "journal-article" @default.
• W4207040364 hasAuthorship W4207040364A5005225798 @default.
• W4207040364 hasAuthorship W4207040364A5006764971 @default.
• W4207040364 hasAuthorship W4207040364A5009301455 @default.
• W4207040364 hasAuthorship W4207040364A5012827962 @default.
• W4207040364 hasAuthorship W4207040364A5016004110 @default.
• W4207040364 hasAuthorship W4207040364A5019369010 @default.
• W4207040364 hasAuthorship W4207040364A5019807753 @default.
• W4207040364 hasAuthorship W4207040364A5022979690 @default.
• W4207040364 hasAuthorship W4207040364A5026626377 @default.
• W4207040364 hasAuthorship W4207040364A5026668616 @default.
• W4207040364 hasAuthorship W4207040364A5030293270 @default.
• W4207040364 hasAuthorship W4207040364A5033603299 @default.
• W4207040364 hasAuthorship W4207040364A5035425491 @default.
• W4207040364 hasAuthorship W4207040364A5040815474 @default.
• W4207040364 hasAuthorship W4207040364A5043871716 @default.
• W4207040364 hasAuthorship W4207040364A5044227648 @default.
• W4207040364 hasAuthorship W4207040364A5052756461 @default.
• W4207040364 hasAuthorship W4207040364A5057439250 @default.
• W4207040364 hasAuthorship W4207040364A5064650836 @default.
• W4207040364 hasAuthorship W4207040364A5070194844 @default.
• W4207040364 hasAuthorship W4207040364A5071618232 @default.
• W4207040364 hasAuthorship W4207040364A5072931455 @default.
• W4207040364 hasAuthorship W4207040364A5073278312 @default.
• W4207040364 hasAuthorship W4207040364A5078564323 @default.
• W4207040364 hasAuthorship W4207040364A5079101221 @default.
• W4207040364 hasAuthorship W4207040364A5081936870 @default.
• W4207040364 hasAuthorship W4207040364A5083639360 @default.
• W4207040364 hasAuthorship W4207040364A5087750390 @default.
• W4207040364 hasAuthorship W4207040364A5088402750 @default.
• W4207040364 hasAuthorship W4207040364A5088977709 @default.
• W4207040364 hasAuthorship W4207040364A5089135490 @default.
• W4207040364 hasAuthorship W4207040364A5089957220 @default.
• W4207040364 hasAuthorship W4207040364A5091740212 @default.
• W4207040364 hasAuthorship W4207040364A9999999999 @default.
• W4207040364 hasBestOaLocation W42070403641 @default.
• W4207040364 hasConcept C120665830 @default.
• W4207040364 hasConcept C121332964 @default.
• W4207040364 hasConcept C126322002 @default.
• W4207040364 hasConcept C168563851 @default.
• W4207040364 hasConcept C187212893 @default.
• W4207040364 hasConcept C203014093 @default.
• W4207040364 hasConcept C22070199 @default.
• W4207040364 hasConcept C2777910003 @default.
• W4207040364 hasConcept C2781413609 @default.

• next